Mass Balance Study of [14C]Eribulin in Patients with Advanced Solid Tumors

Bai, 1991, Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data, J Biol Chem, 266, 15882, 10.1016/S0021-9258(18)98491-7

Beumer, 2006, Mass balance studies, with a focus on anticancer drugs, Clin Pharmacokinet, 45, 33, 10.2165/00003088-200645010-00003

Cigler, 2010, Eribulin mesylate for the treatment of breast cancer, Expert Opin Pharmacother, 11, 1587, 10.1517/14656566.2010.486790

Cortes, 2011, Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study, Lancet, 377, 914, 10.1016/S0140-6736(11)60070-6

Cortes, 2010, Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine, J Clin Oncol, 28, 3922, 10.1200/JCO.2009.25.8467

Currie, 1968, Limits for qualitative detection and quantitative determination. Application to radiochemistry, Anal Chem, 40, 586, 10.1021/ac60259a007

Devriese, 2011, Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole, EJC Supplements, 8, 181, 10.1016/S1359-6349(10)72281-3

Devriese, 2011, Eribulin dosing in patients with advanced solid tumors and hepatic impairment, J Clin Oncol, 29, 2544, 10.1200/jco.2011.29.15_suppl.2544

Dubbelman, 2011, Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices, J Chromatogr B Analyt Technol Biomed Life Sci, 879, 1149, 10.1016/j.jchromb.2011.03.021

Goel, 2009, A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies, Clin Cancer Res, 15, 4207, 10.1158/1078-0432.CCR-08-2429

Hirata, 1986, Halichondrins—antitumor polyether macrolides from a marine sponge, Pure Appl Chem, 58, 701, 10.1351/pac198658050701

Jackson, 2009, The halichondrins and E7389, Chem Rev, 109, 3044, 10.1021/cr900016w

Reyderman, 2011, Eribulin and cytochrome P450 effectors: in vitro studies and population pharmacokinetic–pharmacodynamic analysis, EJC Supplements, 8, 181, 10.1016/S1359-6349(10)72280-1

Synold, 2010, Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): A California Cancer Consortium Trial, J Clin Oncol, 28, 2527

Tan, 2009, Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors, Clin Cancer Res, 15, 4213, 10.1158/1078-0432.CCR-09-0360

Towle, 2001, In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B, Cancer Res, 61, 1013

Vahdat, 2009, Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane, J Clin Oncol, 27, 2954, 10.1200/JCO.2008.17.7618

Vahdat, 2008, Phase II study of eribulin mesylate (E7389) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy, J Clin Oncol, 26, 1084, 10.1200/jco.2008.26.15_suppl.1084

van den Bongard, 2002, An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients, Anticancer Drugs, 13, 807, 10.1097/00001813-200209000-00004

Zhang, 2008, Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4, Cancer Chemother Pharmacol, 62, 707, 10.1007/s00280-008-0755-1

Zhu, 2005, Analysis of low level radioactive metabolites in biological fluids using high-performance liquid chromatography with microplate scintillation counting: method validation and application, J Pharm Biomed Anal, 39, 233, 10.1016/j.jpba.2005.03.012